Radar · Life Sciences in Minnesota
Best Life Sciences Companies in Minnesota, United States
The 392 best Life Sciences companies in Minnesota, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Saluda Medical.
By Riya SenguptaFinancials
392companies tracked
$5.6Bdisclosed funding
0unicorns
211have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × MINNESOTA
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
164companies analysed
83%cloud-native stacks
2025funding peak (by rounds)
7unicorns
2016median founding year
153kcombined LinkedIn audience
45%of audience held by top 3
5companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in Minnesota
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Saluda Medical Developer of neuromodulation platform measuring biomarkers for chronic neurological condition treatment 62Funding top 14%Moat top 31%News top 39%Growth top 42% All 8 signals ▾Fundingtop 14% Moattop 31% Newstop 39% Growthtop 42% Markettop 44% Techtop 45% Talentbottom 49% Globalbottom 43% Funding: Raised $400M across 8 rounds · 8 rounds over 14 yrs (0.6/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 62/100 | $400M | 7 mo ago | Public | 327 | Jim Schuermann CEO | — | 1 launch |
| 2 | CVRx Developer of implantable technology for hypertension and heart failure | $394M | 71 mo ago | Public | 142 142 → 252 (+77%) | — | 284 patents Implantable baroreflex activation devices and minimally invasive electrode delivery systems | 1 partnership |
| 3 | IDRx Developer of precision combination therapies for cancer | $242M | 22 mo ago | Acquired | 19 | Nicholas Lydon Co-Founder | 5 patents Combination cancer therapeutics using KIT inhibitor regimens | — |
| 4 | Nuvaira Provider of a catheter-based system for patients suffering from COPD 57Funding top 18%Moat top 23%Product top 31%Patents top 33% All 11 signals ▾Fundingtop 18% Moattop 23% Producttop 31% Patentstop 33% Innovationtop 35% Growthtop 40% Talentbottom 49% Marketbottom 46% Techbottom 46% Globalbottom 40% Newsbottom 27% Funding: Raised $191M across 10 rounds · 10 rounds over 17 yrs (0.6/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 97 patents rank vs industry peers · Fliar Intelligence Index 57/100 | $191M | 3 mo ago | Series E | 57 | Dennis Wahr CEO | 97 patents Minimally invasive therapeutic devices for respiratory, esophageal and catheter-based interventions | 1 job opening |
| 5 | Monteris Minimally invasive robotic laser thermotherapy 55Funding top 15%Moat top 31%Talent top 38%Market top 43% All 8 signals ▾Fundingtop 15% Moattop 31% Talenttop 38% Markettop 43% Growthtop 48% Newsbottom 42% Techbottom 38% Globalbottom 37% Funding: Raised $174M across 20 rounds · 20 rounds over 18 yrs (1.1/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 55/100 | $174M | 3 mo ago | Series E | 100 100 → 128 (+28%) | Richard Tyc Co-Founder & SVP Science & Technology | — | — |
| 6 | Endogenex Developer of medical devices for the treatment of Type 2 diabetes 37Funding top 18%Innovation top 39%Moat top 39%Patents top 41% All 9 signals ▾Fundingtop 18% Innovationtop 39% Moattop 39% Patentstop 41% Talentbottom 49% Globalbottom 37% Techbottom 35% Marketbottom 31% Newsbottom 20% Funding: Raised $140M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) Innovation: 25 patents (top 67% of patent-holders) · 24 filings since 2022 vs 1 in 2017-21 rank vs industry peers · Fliar Intelligence Index 37/100 | $140M | 2 mo ago | Series C | 15 15 → 27 (+80%) | Michael Brenzel Co-Founder & CTO | 25 patents Pulsed electric field electroporation devices for tissue ablation, especially gastrointestinal applications. | 1 launch |
| 7 | Anteristech Provider of technologies for developing heart valve | $126M | 7 mo ago | Public | 27 | — | — | — |
| 8 | Flywheel Cloud based data research platform 80Funding top 14%AI top 20%Product top 21%Moat top 31% All 10 signals ▾Fundingtop 14% AItop 20% Producttop 21% Moattop 31% Innovationtop 32% Techtop 33% Growthtop 35% Talenttop 38% Marketbottom 49% Globalbottom 39% Funding: Raised $110M across 10 rounds · 10 rounds over 8 yrs (1.2/yr) AI: Classified as an AI company rank vs industry peers · Fliar Intelligence Index 80/100 | $110M | 5 mo ago | Series D | 160 | Gunnar Schaefer Co-Founder | — | 1 partnership |
| 9 | Neochord Provider of minimally -invasive devise for valve repair | $108M | 15 mo ago | Series E | 7 | David Chung President & CEO | 142 patents Minimally invasive cardiac valve repair devices and suture anchoring technologies | — |
| 10 | ShiraTronics Developer of a neuromodulating device for treating migraine | $108M | 21 mo ago | Series B | 29 | — | 67 patents Implantable neurostimulation devices for headache relief with wireless charging and communication | — |
| 11 | Vyriad Developer of oncolytic-virus-based immunotherapies for cancer treatment 50Patents top 20%Funding top 21%Innovation top 25%Moat top 32% All 7 signals ▾Patentstop 20% Fundingtop 21% Innovationtop 25% Moattop 32% Techbottom 43% Globalbottom 37% Marketbottom 36% Patents: 70 patents matched (strict assignee match) · 56 filings since 2022 vs 14 in 2017-21 Funding: Raised $100M across 8 rounds · 8 rounds over 8 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 50/100 | $100M | 5 mo ago | Series B | 37 | — | 70 patents Engineered rhabdoviral vectors for cancer immunotherapy and viral antibody diagnostics | — |
| 12 | Sonex Health Innovating ultrasound-guided solutions to transform patient experience, improve safety, lower costs | $90M | 33 mo ago | Series B | 32 | Jay Smith Co-Founder & CMO | — | — |
| 13 | 4C Medical Developer of medical devices for the treatment of mitral regurgitation | $88M | 15 mo ago | Series D | 28 | Jeffrey Chambers Founder | 547 patents Minimally invasive electrosurgical instruments and RF‑activated surgical systems for laparoscopy | — |
| 14 | Francis Medical Developer of a therapeutic solution to treat prostate, kidney, and bladder cancer | $77M | 18 mo ago | Series C | 29 | — | — | 2 launchs |
| 15 | Recombinetics Developer of gene repair and gene-editing technology to create animal models 35Moat top 19%Funding top 30%Patents top 32%Product top 36% All 10 signals ▾Moattop 19% Fundingtop 30% Patentstop 32% Producttop 36% Innovationtop 37% Globalbottom 42% Growthbottom 41% Techbottom 36% Marketbottom 33% Newsbottom 22% Moat: Editorial + unicorn rating 8/10 · IP moat: 242 patents Funding: Raised $66.8M across 25 rounds · 25 rounds over 15 yrs (1.7/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $67M | 14 mo ago | Series A | 29 29 → 17 (-41%) | — | 242 patents Livestock genome engineering via pluripotent stem cells and non-meiotic allele introgression | — |
| 16 | MIVI Neuroscience Developer of catheters for acute ischemic stroke therapy | $66M | 34 mo ago | Series C | 37 | — | 98 patents Neurovascular catheter systems for aspiration, thrombectomy, and embolic protection in cerebral vessels | — |
| 17 | Cytotheryx Developer of human hepatocytes for research and clinical applications 29Moat top 30%Patents top 37%Funding top 38%Innovation top 41% All 7 signals ▾Moattop 30% Patentstop 37% Fundingtop 38% Innovationtop 41% Talentbottom 49% Globalbottom 35% Marketbottom 25% Moat: IP moat: 14 patents · Soonicorn Patents: 14 patents matched (strict assignee match) · 14 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 29/100 | $60M | 5 mo ago | Series A | 12 | John Swart Chief Executive Officer | 14 patents Engineered human hepatocyte production, genetic modification, and biliary delivery platforms | — |
| 18 | Aria CV Device for pulmonary hypertension | $44M | 10 mo ago | Series B | 17 | Dan Gladney Chief Executive Officer | 59 patents Implantable cardiovascular pressure-regulating devices for pulmonary hypertension treatment | — |
| 19 | Predictive Oncology AI-based cancer diagnostic and precision medicines platform 42Funding top 31%Tech top 41%AI top 45%Moat top 48% All 10 signals ▾Fundingtop 31% Techtop 41% AItop 45% Moattop 48% Fin. healthbottom 49% Talentbottom 49% Newsbottom 41% Growthbottom 40% Globalbottom 37% Marketbottom 33% Funding: Raised $43.0M across 9 rounds · 9 rounds over 18 yrs (0.5/yr) Tech: 51 technologies across 3/8 capability areas · Cloud: Akamai, Amazon Web Services rank vs industry peers · Fliar Intelligence Index 42/100 | $43M | 8 mo ago | Acquired | 31 | Carl Schwartz CEO | — | — |
| 20 | KORONIS BIOMEDICAL TECHNOLOGIES Developer of sensors for diagnosis of lung diseases | $40M | 9 mo ago | Funding Raised | — | — | — | — |
| 21 | FOXO Technologies Provider of epigenetic biomarkers discovery and development platform | $40M | 12 mo ago | Public | 15 | — | 3 patents Machine‑learning analysis and quality control of epigenetic DNA data for health diagnostics | — |
| 22 | Cryosa Provider of a therapeutic medical device for treating sleep disorders | $30M | 11 mo ago | Series B | 16 16 → 13 (-19%) | — | 50 patents Cryogenic adipose tissue ablation devices for obstructive sleep apnea treatment | — |
| 23 | iVEAcare Developer of neuromodulation technology intended to treat patients suffering from chronic diseases | $28M | 25 mo ago | Series A | — | Mudit Jain Co-Founder | 5 patents Personalized vagus nerve stimulation and AI-driven seizure/depression monitoring | — |
| 24 | Veravas Provider of platform to manage sample preparation and diagnostic solutions | $25M | 27 mo ago | Series A | 4 | John Forrest Founder and Executive Chairman | 51 patents Multiplex biosensor platforms for detecting and enriching disease biomarkers | 1 award |
| 25 | Reprise Biomedical Developer of surgical mesh for wound management | $23M | 1 mo ago | Series B | 16 | Carrie Powers Chief Executive Officer | — | — |
| 26 | Preceptis Medical Surgical tool for ear tube procedures | $19M | 2 mo ago | Series B | 4 | — | — | — |
| 27 | PamGene Provider of a microarray platform and gene expression profiling system for post-genomic applications | $18M | 35 mo ago | Series B | 38 | — | — | 1 partnership |
| 28 | Vascudyne Developer of regenerative biomaterials for tissue repair and replacement | $18M | 13 mo ago | Series A | 6 | Jeff Franco Co-Founder | 40 patents Engineered tissue implants for cardiovascular valves, grafts, and nerve repair | 1 award |
| 29 | Alpheus Medical Developer of Sonodynamic therapy device for brain cancer | $16M | 13 mo ago | Series B | 7 | Vijay Agarwal Founder & CEO | — | — |
| 30 | Cardio Flow Developer of orbital atherectomy platform for treating calcified and fibrotic plaque | $16M | 24 mo ago | Series A | 2 | Michael Kallok President and CEO | 170 patents Coronary rotational atherectomy and intravascular lithotripsy devices for plaque removal | — |
| 31 | Celcuity Developer of targeted therapies for cancer patients | $15M | 32 mo ago | Public | 42 | — | 74 patents Predictive biomarker assays and companion diagnostics for PI3K/mTOR cancer therapies | — |
| 32 | Humanetics Corporation Clinical-stage biopharma company developing radiation modulators as therapeutics for solid cancers | $13M | 31 mo ago | Funding Raised | 4 | Ronald Zenk Chief Executive Officer and member of the Board of Directors | 99 patents Pharmaceutical genistein formulations for inflammatory/respiratory disorders and radiation sensitizers. | — |
| 33 | Piraeus Medical Developer of solutions for stroke thrombectomy procedures | $11M | 2 mo ago | Series B | — | Jared Hutar Chief Executive Officer | — | — |
| 34 | ABM Respiratory Care Developer of devices for ventilation and airway clearance 45Growth top 35%Moat top 38%Funding top 40%Product top 40% All 9 signals ▾Growthtop 35% Moattop 38% Fundingtop 40% Producttop 40% Techtop 47% Talentbottom 49% Marketbottom 39% Globalbottom 37% Newsbottom 18% Growth: Fresh capital in last 24 mo Moat: Editorial + unicorn rating 5/10 · 1 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 45/100 | $10M | 11 mo ago | Series B | 54 | Vinay Joshi CTO and Founder | — | — |
| 35 | AdvancedCPR Solutions Improving CPR outcomes through innovative patient positioning solutions and training | $10M | 16 mo ago | Series A | 10 | Phil Faris Co-Founder & CEO | — | — |
| 36 | MarPam Pharma Provider of chimeric antigen receptor (CAR) based therapeutics solution for treating HIV | $9M | 14 mo ago | Funding Raised | 5 | — | — | — |
| 37 | InSitu Biologics Developer of multi-phase prolonged release drug delivery platform for localized treatments | $8M | 7 mo ago | Series A | 7 | Bill Taylor Co-Founder & Chief Science Officer | 29 patents Patents concentrated in health & consumer products | — |
| 38 | Eden Medical Developer of medical device for the treatment of wounds | $8M | 21 mo ago | Funding Raised | — | Jeffrey Schoess President and CEO | — | — |
| 39 | Phenomix Sciences Provider of test for personalized management of obesity | $8M | 5 mo ago | Series A | 9 | Michael Camilleri Co-Founder | — | — |
| 40 | Minnesota Medical Technologies Provider of medical technology services for people suffering from incontinence | $7M | 6 mo ago | Series A | 15 | David Jonas CEO | — | — |
| 41 | Aplos Medical Developer of an implant to treat acid reflux disease | $5M | 9 mo ago | Funding Raised | — | Claude Tihon Founder & CEO | — | — |
| 42 | Minnesota Medical Technologies Manufacturer of continence care products | $5M | 19 mo ago | Series A | — | Anthony Conway Co-Founder & President | — | — |
| 43 | Luminary Developer of cell therapies for treating cancer | $3M | 8 mo ago | Series B | 8 | — | 6 patents Patents concentrated in health & consumer products | — |
| 44 | EmpNia Developer of precision imaging and radiation therapy for the treatment of cancer patients | $3M | 6 mo ago | Series B | — | Manojeet Bhattacharya Founder & CEO-EmpNia | University of Notre Dame PhD 1998 | 26 patents Real-time respiratory motion monitoring and gating for medical imaging and therapy | — |
| 45 | Be The Match Provider of cell therapy research, patient support, and donor registry | $3M | 10 mo ago | Funding Raised | 2,281 | — | 126 patents AI-driven social networking recommendation and remote conversation facilitation platforms | — |
| 46 | Agitated Solutions Developer of treatment for hypoxemic respiratory failure | $3M | 10 mo ago | Series A | — | Morgan Clyburn Co-Founder & CEO | 30 patents Microbubble contrast agents and ultrasound‑guided imaging/therapy devices for cardiac and musculoskeletal diagnostics. | — |
| 47 | Neuroglide Developer of automated lymphatic drainage therapy for pain relief and lymphatic health | $852K | 13 mo ago | Seed | — | Irene Waldridge Founder & CEO & CTO | — | — |
| 48 | Nascent Surgical Smoke evacuation solutions for cleaner operating rooms and improved patient outcomes | $583K | 14 mo ago | Series A | 3 | Leonard Schultz Founder | 23 patents Surgical smoke and aerosol evacuation systems for operating rooms | — |
| 49 | AcQumen Medical Developer of hemodynamic monitor providing continuous cardiac output for pediatric patients | $341K | 7 mo ago | Seed | — | Rodney Houfburg Co-Founder & CTO | — | 1 award |
| 50 | Niche Biopharmaceuticals Developer of novel anti-infective and anti-inflammatory therapeutics | $300K | 1 mo ago | Seed | — | Dayton Reardan Founder & CEO | 9 patents Sulfur‑based glycerol monoester compounds for antimicrobial and antiviral therapeutics | — |
Top 12 Life Sciences companies in Minnesota
#1
Series E · Plymouth, Minnesota · founded 1999 · 100 employees$174.3Mraised▾
Series E · Plymouth, Minnesota · founded 1999 · 100 employees
Monteris Medical is focused on providing innovative MRI-guided neurosurgical ablation tools and solutions for neurosurgeons. By combining the imaging power of Magnetic Resonance Imaging (MRI), advanced navigation software and Laser Interstitial Thermal Therapy (LITT), Monteris Medical has created a system to reach virtually any area of the brain.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Funding
top 15%Moat
top 31%Talent
top 38%Market
top 43%Growth
top 48%News
bottom 42%Funding: Raised $174M across 20 rounds · 20 rounds over 18 yrs (1.1/yr) · Last round Conventional Debt (Mar 2026)
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 9 curated direct competitors tracked
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 15k LinkedIn followers — 9.8% of this cohort's audience
Funding rounds
- Mar 2026Series E$28M
- Mar 2026Conventional Debt$35M
- Oct 2022Conventional Debt$38M
- Oct 2022Series D$35M
Founders & team
Investors
BDC, The Vertical Group, Oxford Finance, Madryn Asset Management, InnovaHealth Partners, Birchview Capital
Tech stack
WordpressMysqlPhpContact Form 7Yoast SeoSite Kit
#2
Series C · Plymouth, Minnesota · founded 2017 · 15 employees$140.4Mraised▾
Series C · Plymouth, Minnesota · founded 2017 · 15 employees
Developer of medical devices for the treatment of Type 2 diabetes. The company has developed a novel therapy that utilizes pulsed electric fields to promote regeneration of the duodenal mucosa for improvement in glycemic control in patients with Type 2 diabetes.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Funding
top 18%Innovation
top 39%Moat
top 39%Patents
top 41%Talent
bottom 49%Global
bottom 37%Funding: Raised $140M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) · Last round Series C (Mar 2026)
Innovation: 25 patents (top 67% of patent-holders) · 24 filings since 2022 vs 1 in 2017-21 · Deep-tech classification: Tech Hardware
Moat: Editorial + unicorn rating 3/10 · IP moat: 25 patents · Soonicorn
Audience (LinkedIn): 4k LinkedIn followers — 2.4% of this cohort's audience
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: transformative healthcare
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Mar 2026Series C$50M
- Jun 2024Series C$88M
- Oct 2023Series B$18.3M
- Feb 2023Series A$9.2M
Founders & team
Investors
FDA, Hatteras Venture Partners, Lumira Ventures, Orlando Health, Intuitive, Longitude Capital
#3
Series E · Minneapolis, Minnesota · founded 2008 · 57 employees$191.1Mraised▾
Series E · Minneapolis, Minnesota · founded 2008 · 57 employees
Provider of a catheter-based system for patients suffering from COPD. The company is developing Nuvaira Lung Denervation System, a catheter-based system used to treat the overactive airway nerves in a procedure called Targeted Lung Denervation (TLD). It provides an ablative therapy that opens obstructed airways to improve breathing.
Fliar Intelligence Index™ 57how this company ranks against its industry peers
Funding
top 18%Moat
top 23%Product
top 31%Patents
top 33%Innovation
top 35%Growth
top 40%Funding: Raised $191M across 10 rounds · 10 rounds over 17 yrs (0.6/yr) · Last round Series E (Feb 2026)
Moat: Editorial + unicorn rating 8/10 · IP moat: 97 patents · Soonicorn
Product: 2 distinct product lines · Company stage: Series E
Audience (LinkedIn): 6k LinkedIn followers — 3.7% of this cohort's audience
Hiring (LinkedIn): 3 hiring posts in 12 mo (public) · momentum -1 · hiring: Director/Sr. Director of Clinical, Director / Senior Director of Clinical
Funding rounds
- Feb 2026Series E$35.8M
- Nov 2023Series E$15.1M
- Jan 2022Series E$31.3M
- Feb 2019Series E$79M
Founders & team
Investors
Advanced Technology Ventures, Morgenthaler, Split Rock Partners, Versant Ventures, USVP, Endeavour Vision
Tech stack
Apple Icloud MailCloudflareCloudflare Bot ManagementDocusignGodaddyGoogle Analytics
#4
Public · Bloomington, Minnesota · founded 2010 · 327 employees$400Mraised▾
Public · Bloomington, Minnesota · founded 2010 · 327 employees
Developer of neuromodulation platform measuring biomarkers for chronic neurological condition treatment. It offers a system that measures and records neural activation characteristics. The system quantifies stimulation levels to a clinician-defined target, continuously comparing neural activation with the target level. It automatically adjusts stimulation current to ensure consistent neural activation. The company focuses on neuromodulation solutions for chronic pain. It utilizes Evoked Compound Action Potentials to advance neuromodulation therapy.
Fliar Intelligence Index™ 62how this company ranks against its industry peers
Funding
top 14%Moat
top 31%News
top 39%Growth
top 42%Market
top 44%Tech
top 45%Funding: Raised $400M across 8 rounds · 8 rounds over 14 yrs (0.6/yr) · Last round Series F (Oct 2025)
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 9 curated direct competitors tracked
News: 3 BI events in 12 mo (of 22 tracked, 4 types) · +50% YoY · Top themes: IPO
Audience (LinkedIn): 34k LinkedIn followers — 22.3% of this cohort's audience
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Oct 2025Series F$30M
- Jan 2025Series F$100M
- Apr 2023Series F$150M
- Mar 2022Series F$125M
Founders & team
Investors
Medtronic, Boston Scientific, Redmile Group, Action Potential Venture Capital, BioScience Managers, NSW Health
Tech stack
Apple Icloud MailAutoptimizeAzureCloudflareCloudflare Bot ManagementCookieyes
#5
Series D · Minneapolis, Minnesota · founded 2015 · 160 employees$110Mraised▾
Series D · Minneapolis, Minnesota · founded 2015 · 160 employees
Cloud based data research platform. It is a data research platform provider for the healthcare industry. It provides a platform for data capture, analysis, and research sharing. It also provides a platform for researchers to help in data capture, analysis, and research sharing. It allows data migration for importing data into its systems and combining data from multiple data sets.
Fliar Intelligence Index™ 80how this company ranks against its industry peers
Funding
top 14%AI
top 20%Product
top 21%Moat
top 31%Innovation
top 32%Tech
top 33%Funding: Raised $110M across 10 rounds · 10 rounds over 8 yrs (1.2/yr) · Last round Series D (Dec 2025)
AI: Classified as an AI company
Product: 4 distinct product lines · Company stage: Series D
Audience (LinkedIn): 8k LinkedIn followers — 5.1% of this cohort's audience
Activity (LinkedIn): 1 partnerships (incl. AWS HealthImaging) announced in 12 mo
Funding rounds
- Dec 2025Series D$27.5M
- Oct 2025Series D$2.3M
- May 2025Grant (prize money)$8.7M
- Dec 2024Series D$20M
Founders & team
Investors
8VC, Argonautic, dRx Capital, iSelect Fund, Beringea, Alumni Ventures
Tech stack
AccessibeBackbone.JsBootstrapCloudflareCloudflare Bot ManagementCookiefirst
#6
Series B · Rochester, Minnesota · founded 2016 · 37 employees$100Mraised▾
Series B · Rochester, Minnesota · founded 2016 · 37 employees
Developer of oncolytic-virus-based immunotherapies for cancer treatment. The company focuses on the development of new oncolytic virus treatments that leverage Vyriad’s vesicular stomatitis virus (VSV) platform, as well as antibody discovery capabilities. The company's lead product is Voyager-V1 which addresses multiple cancer types.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Patents
top 20%Funding
top 21%Innovation
top 25%Moat
top 32%Tech
bottom 43%Global
bottom 37%Patents: 70 patents matched (strict assignee match) · 56 filings since 2022 vs 14 in 2017-21 · Latest publication 2026
Funding: Raised $100M across 8 rounds · 8 rounds over 8 yrs (1.0/yr) · Last round Series B (Dec 2025)
Innovation: 70 patents (top 25% of patent-holders) · 56 filings since 2022 vs 14 in 2017-21
Audience (LinkedIn): 5k LinkedIn followers — 3.3% of this cohort's audience
Funding rounds
- Dec 2025Series B$25M
- May 2022Series B$29.5M
- Oct 2019Series A$24.4M
- Sep 2018Grant (prize money)$2.1M
Investors
Mayo Clinic, Mirae Asset, Regeneron Pharmaceuticals, Southeast Minnesota Capital Fund, Minnesota.gov, Rochester Area Economic Development
#7
Series B · Plymouth, Minnesota · founded 2019 · 16 employees$23.1Mraised▾
Series B · Plymouth, Minnesota · founded 2019 · 16 employees
Developer of surgical mesh for wound management. The products developed are FDA-approved MIRODERM (derived from the porcine liver) and MIROMESH (non-crosslinked acellular surgical mesh) that uses perfusion decellularization technology. It is used to treat wounds, ulcers, venous ulcers, chronic vascular ulcers, diabetic ulcers, tunneled and undermined wounds, trauma wounds, drainage wounds, and surgical wounds.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 3k LinkedIn followers — 2.2% of this cohort's audience
Funding rounds
- Jun 2025Series B$6.4M
- Jan 2023Series B$15.3M
- Mar 2021Series A$5M
- Nov 2020Seed$2.8M
Founders & team
Investors
Lateral Capital
Tech stack
Apple Icloud MailCloudflareCloudflare Bot ManagementComplianzDiviFont Awesome
#8
Public · Eagan, Minnesota · founded 2006 · 27 employees$126.2Mraised▾
Public · Eagan, Minnesota · founded 2006 · 27 employees
Provider of technologies for developing heart valve. The company has developed a 3D single-piece aortic valve called the DurAVR heart valve that uses its patented ADAPT technology. The other products developed are DurAVR leaflet repair (RP), DurAVR transcatheter heart valve (THV), DurAVR surgical heart valve (SHV).
LinkedIn Pulse recent public activity · Jul 2026
Audience: 12k LinkedIn followers — 7.6% of this cohort's audience · 98 engagements/post (2.9× cohort median)
Funding rounds
- Oct 2025Post IPO$11.5M
- Apr 2024Post IPO$15.2M
- Mar 2022Post IPO$20M
- Oct 2021Post IPO$3.8M
Investors
Mercer, Perceptive Advisors, Star Bright Holding, HHS, Lifeblood Capital
Tech stack
Adobe AnalyticsAdobe Client Data LayerAdobe Experience ManagerAdobe Experience Platform LaunchApple Icloud MailBamboohr
#9
Series B · Minneapolis, Minnesota · founded 2011 · 4 employees$19.2Mraised▾
Series B · Minneapolis, Minnesota · founded 2011 · 4 employees
Preceptis Medical is a medical device manufacturer developing surgical tools that allow ear tube procedures to be performed with reduced pain and surgical time for the pediatric patient. Its product, The HUMMINGBIRD TTS Tympanostomy Tube System, gives physicians the option to perform the procedure using moderate or conscious sedation. The device is not commercially available. Participated with Mayo Clinic and Children’s Hospitals and Clinics of Minnesota clinical study.
Funding rounds
- Apr 2026Series B$2.6M
- Dec 2020Series B$3.2M
- Mar 2020Series B$3.7M
- Jun 2018Series B$6M
Investors
Partisan Management Group, Atlas Capital Partners, Heuristic Capital Partners, Omphalos Ventures, BrilliMedical
#10
Series A · Rochester, Minnesota · founded 2018 · 12 employees$60Mraised▾
Series A · Rochester, Minnesota · founded 2018 · 12 employees
Developer of human hepatocytes (HHC) for research and clinical applications. The company develops HHC for toxicology study, hepatitis research, and allotransplants.
Fliar Intelligence Index™ 29how this company ranks against its industry peers
Moat
top 30%Patents
top 37%Funding
top 38%Innovation
top 41%Talent
bottom 49%Global
bottom 35%Moat: IP moat: 14 patents · Soonicorn
Patents: 14 patents matched (strict assignee match) · 14 filings since 2022 vs 0 in 2017-21 · Latest publication 2025
Funding: Raised $60.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Conventional Debt (Jan 2026)
Audience (LinkedIn): 1k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Cell Production Manager
Activity (LinkedIn): 1 expansions announced in 12 mo
Funding rounds
- Jan 2026Conventional Debt—
- Jan 2026Series A$60M
Founders & team
Investors
QRS Investments, Ouroboros Family Founders Fund I, Hill Capital
#11
Series B · Maple Grove, Minnesota · founded 2021$11Mraised▾
Series B · Maple Grove, Minnesota · founded 2021
Developer of solutions for stroke thrombectomy procedures. It offers Wrist-to-Brain thrombectomy system that combines an introducer sheath, guide catheter, and distal access catheter into one device to improve the care of patients suffering from Acute Ischemic Stroke.
Funding rounds
- Mar 2026Series B$3.6M
- Oct 2025Series A$662.6K
- Sep 2025Series A$300K
- Feb 2025Series A$2M
Founders & team
Investors
HHS
#12
Acquired · Eagan, Minnesota · founded 2002 · 31 employees$43Mraised▾
Acquired · Eagan, Minnesota · founded 2002 · 31 employees
AI-based cancer diagnostic and precision medicines platform. The company has developed an AI-based assessment and inventory for precision medicine and treatment planning. The system uses Multi-omics models analysis and diagnostic technology for decision making.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Funding
top 31%Tech
top 41%AI
top 45%Moat
top 48%Fin. health
bottom 49%Talent
bottom 49%Funding: Raised $43.0M across 9 rounds · 9 rounds over 18 yrs (0.5/yr) · Last round Post IPO (Oct 2025)
Tech: 51 technologies across 3/8 capability areas · Cloud: Akamai, Amazon Web Services · Security: Cloudflare Bot Management, Hsts
AI: Product described with: ai-based
Audience (LinkedIn): 2k LinkedIn followers
Funding rounds
- Oct 2025Post IPO$50.8M
- Aug 2025Post IPO$413.1K
- May 2022Post IPO$2.3M
- Mar 2021Post IPO$34.4M
Founders & team
Investors
Longitude Capital, Adams Capital Management, Quaker Partners Management, Birchmere Ventures, TVM, Draper Triangle
Tech stack
AstraCloudflareCloudflare Bot ManagementCore-JsDemandbaseElementor
Funding & investor landscape
$5.6Btotal disclosed funding
219companies funded
815disclosed rounds
4rounds last 90 days
Most active investors
New Enterprise Associates7 rounds
Notable founders
Richard Tyc
Co-Founder & SVP Science & Technology · Monteris
James Duncan
Co-CEO · Monteris
Michael Brenzel
Co-Founder & CTO · Endogenex
Dennis Wahr
CEO · Nuvaira
Jim Schuermann
CEO · Saluda Medical
Gunnar Schaefer
Co-Founder · Flywheel
Troy Kopischke
Co-Founder · Flywheel
Carrie Powers
Chief Executive Officer · Reprise Biomedical
John Swart
Chief Executive Officer · Cytotheryx
Jared Hutar
Chief Executive Officer · Piraeus Medical
Carl Schwartz
CEO · Predictive Oncology
Dan Gladney
Chief Executive Officer · Aria CV
Prism market signals · United States · country-scoped Prism corpus, 1,465,538 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH IN MINNESOTA · Health & Bio
How research on Biotechnology in Minnesota is moving
A read on the academic research around Biotechnology in Minnesota — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 82 papers.
University of Minnesota leads Minnesota's biotechnology research, focusing on immune cell function, CRISPR, and CAR-T therapy, with a cautiously optimistic tone (mean stance 0.48) skewing toward breakthroughs.
82 papers · stance +0.48 · 46% breakthrough · 21% concern
top institutions
- University of Minnesota66
- University of Minnesota Medical Center12
- University of Minnesota System8
- Minnesota State Community and Technical College2
- Minnesota Department of Health2
leading researchers
Anna J DesMarais · Araújo, Yuri · Carvalho, Clara · Costa, Rayany · David H. McKenna · Feng Zhang
prism intelligence · tone & topics
93% positive · 0% critical tone
HealthAgricultureMedical ResearchPharmaceuticalsGeneticsBiology
▲
Breakthroughs33 · 40%
▲ 39%→41% share
▲1.1× share momentum0 median citations73% since 2021mostly empirical
Gene and Messenger RNA research intensifying — combined papers doubled from 3 to 7, driving Breakthroughs to 41% field-share.
rising sub-themes (early→recent)
- Messenger RNA1→3
- Gene2→4
Newly emergingDNA damage 0→3
Landmark Targeting DNA Double-Strand Breaks with TAL Effector Nucleases · 1,987 cites
◆
Advancements24 · 29%
▲ 17%→34% share
▲2.0× share momentum0 median citations83% since 2021mostly empirical
Fermentation research newly emerged with 3 papers, helping Advancements field-share surge from 17% to 34%.
rising sub-themes (early→recent)
- Fermentation3
- Microbiome2
- Beekeeping2
- Food additive2
- Characterization (materials science)2
Newly emergingFermentation 0→3
Landmark Redefining agricultural yields: from tonnes to people nourished per hectare · 657 cites
▼
Concerns15 · 18%
▼ 22%→14% share
▼0.6× share momentum1 median citations53% since 2021mostly empirical
Concerns segment cooling — field-share dropped from 22% to 14% despite Transmission, Agriculture, and Computational Biology each holding 2 papers.
rising sub-themes (early→recent)
- Transmission (telecommunications)2
- Agriculture2
- Computational biology2
- Genetics2
- Public health1
Landmark The growing burden of foodborne outbreaks due to contaminated fresh produce: risks and opportunities · 801 cites
Common questions
How many Life Sciences companies are there in Minnesota, United States?
Radar tracks 392 indexable Life Sciences companies headquartered in Minnesota, United States that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in Minnesota, United States?
The Life Sciences companies in Minnesota, United States on this list have raised a combined $5.6B in disclosed equity funding across 219 funded companies.
Which is the highest-funded Life Sciences company in Minnesota, United States?
Saluda Medical is the highest-funded Life Sciences company in Minnesota, United States, with $400M in disclosed equity funding.
How many Life Sciences companies in Minnesota, United States are funded?
219 of the 392 Life Sciences companies in Minnesota, United States on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in Minnesota, United States?
None of the Life Sciences companies in Minnesota, United States on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in Minnesota, United States Life Sciences companies?
The most active investors in Minnesota, United States Life Sciences companies on this list include HHS, Affinity Capital Management, Mayo Clinic Ventures, NIH, Southeast Minnesota Capital Fund.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.